Scholars@Duke
Murat Osman Arcasoy

Murat Osman Arcasoy

Professor of Medicine
Medicine, Hematology
arcas001@mc.duke.edu
Duke Box 3912, Durham, NC 27710
Hosp South Trent Drive, Box 3912 DUMC, Durham, NC 27710
Manage Profile
Embed Profile Data

Selected Publications

Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.

Journal Article Clin Adv Hematol Oncol · March 2024 The treatment landscape for BCR/ABL-negative myeloproliferative neoplasms (MPNs), driven by JAK2, CALR, and MPL mutations, has evolved significantly over the last decade. Recent regulatory approvals in polycythemia vera (PV) include the JAK inhibitor ruxol ... Link to item Cite

Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.

Journal Article Bone Marrow Transplant · February 2024 Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF) and is recommended for patients with higher risk disease. However, there is a risk of early mortality, and optimal timing is unknown. JAK inhibitor (JAK ... Full text Link to item Cite

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.

Journal Article Blood · May 12, 2022 The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera (PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and interferon-α (IFN-α) are the most frequently used cytoreductive options for pat ... Full text Link to item Cite

Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study.

Journal Article Clin Lymphoma Myeloma Leuk · May 2022 INTRODUCTION: Treatment options in patients with myelofibrosis (MF) presenting with thrombocytopenia are limited. Final results of the phase 2 study (NCT01348490) of ruxolitinib in patients with MF and low baseline platelet counts (50 - 100 × 109/L) are re ... Full text Link to item Cite

Effective Pain Control With Very Low Dose Palliative Radiation Therapy for Patients With Multiple Myeloma With Uncomplicated Osseous Lesions.

Journal Article Adv Radiat Oncol · 2021 BACKGROUND: Osteolytic lesions are present in 75% of patients with multiple myeloma (MM) and frequently require palliation with radiation therapy (RT). Prior case series of patients with MM with bone pain undergoing palliative RT suggests doses ≥12 Gy (equ ... Full text Link to item Cite

Immune Thrombocytopenia Associated with Hepatitis B Virus and Autoimmune Hepatitis and Recovery of Platelet Count following Liver Transplantation.

Journal Article Case Rep Transplant · 2021 Immune thrombocytopenia is a consumptive coagulopathy that can be either idiopathic or associated with infectious or autoimmune etiologies. Here, we present a case of immune thrombocytopenia in the setting of acute liver failure due to coexisting diagnoses ... Full text Link to item Cite

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Conference Blood · November 5, 2020 IntroductionAllogeneic hematopoietic cell transplantation (HCT) remains the only potentially curative therapy for myelofibrosis (MF). However, despite improvements in donor availability, most patients receive non-HC ... Full text Cite

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.

Journal Article Blood Adv · September 22, 2020 Momelotinib (MMB) is a JAK1/2 and ACVR1 inhibitor with demonstrated clinical activity in all 3 hallmarks of myelofibrosis (MF): anemia, constitutional symptoms, and splenomegaly. In this phase 2 open-label translational biology study (NCT02515630) of 41 tr ... Full text Link to item Cite

Survival following allogeneic transplant in patients with myelofibrosis.

Journal Article Blood Adv · May 12, 2020 Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT ... Full text Open Access Link to item Cite

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Conference Blood · November 13, 2019 BackgroundInterferons are recognized as active agents in the treatment of patients with high risk essential thrombocythemia (ET) or polycythemia vera (PV), both in the upfront setting as well as beyond. Several tria ... Full text Cite

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.

Journal Article Blood · October 31, 2019 Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). To further define the role of rIFN-α, we investigated the outcomes of pegylated-rIFN- ... Full text Link to item Cite

Feasibility of myelosuppressive chemotherapy in psychiatric patients on clozapine: A systematic review of the literature.

Journal Article Eur J Haematol · October 2019 OBJECTIVE: Clozapine is the favoured antipsychotic for treatment-refractory schizophrenia, but has a 1%-2% incidence of agranulocytosis. Patients who require chemotherapy therefore pose a unique management dilemma for haematologists, oncologists and psychi ... Full text Link to item Cite

ZCCHC8, the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation.

Journal Article Genes Dev · October 1, 2019 Short telomere syndromes manifest as familial idiopathic pulmonary fibrosis; they are the most common premature aging disorders. We used genome-wide linkage to identify heterozygous loss of function of ZCCHC8, a zinc-knuckle containing protein, as a cause ... Full text Link to item Cite

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Conference Blood · November 29, 2018 AbstractIntroductionHU is the treatment of choice for patients (pts) with high risk ET/PV, however, PEG has been proposed as an alternative option due to its proposed potenti ... Full text Cite

Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.

Journal Article Clin Adv Hematol Oncol · March 2024 The treatment landscape for BCR/ABL-negative myeloproliferative neoplasms (MPNs), driven by JAK2, CALR, and MPL mutations, has evolved significantly over the last decade. Recent regulatory approvals in polycythemia vera (PV) include the JAK inhibitor ruxol ... Link to item Cite

Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.

Journal Article Bone Marrow Transplant · February 2024 Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF) and is recommended for patients with higher risk disease. However, there is a risk of early mortality, and optimal timing is unknown. JAK inhibitor (JAK ... Full text Link to item Cite

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.

Journal Article Blood · May 12, 2022 The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera (PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and interferon-α (IFN-α) are the most frequently used cytoreductive options for pat ... Full text Link to item Cite

Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study.

Journal Article Clin Lymphoma Myeloma Leuk · May 2022 INTRODUCTION: Treatment options in patients with myelofibrosis (MF) presenting with thrombocytopenia are limited. Final results of the phase 2 study (NCT01348490) of ruxolitinib in patients with MF and low baseline platelet counts (50 - 100 × 109/L) are re ... Full text Link to item Cite

Effective Pain Control With Very Low Dose Palliative Radiation Therapy for Patients With Multiple Myeloma With Uncomplicated Osseous Lesions.

Journal Article Adv Radiat Oncol · 2021 BACKGROUND: Osteolytic lesions are present in 75% of patients with multiple myeloma (MM) and frequently require palliation with radiation therapy (RT). Prior case series of patients with MM with bone pain undergoing palliative RT suggests doses ≥12 Gy (equ ... Full text Link to item Cite

Immune Thrombocytopenia Associated with Hepatitis B Virus and Autoimmune Hepatitis and Recovery of Platelet Count following Liver Transplantation.

Journal Article Case Rep Transplant · 2021 Immune thrombocytopenia is a consumptive coagulopathy that can be either idiopathic or associated with infectious or autoimmune etiologies. Here, we present a case of immune thrombocytopenia in the setting of acute liver failure due to coexisting diagnoses ... Full text Link to item Cite

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Conference Blood · November 5, 2020 IntroductionAllogeneic hematopoietic cell transplantation (HCT) remains the only potentially curative therapy for myelofibrosis (MF). However, despite improvements in donor availability, most patients receive non-HC ... Full text Cite

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.

Journal Article Blood Adv · September 22, 2020 Momelotinib (MMB) is a JAK1/2 and ACVR1 inhibitor with demonstrated clinical activity in all 3 hallmarks of myelofibrosis (MF): anemia, constitutional symptoms, and splenomegaly. In this phase 2 open-label translational biology study (NCT02515630) of 41 tr ... Full text Link to item Cite

Survival following allogeneic transplant in patients with myelofibrosis.

Journal Article Blood Adv · May 12, 2020 Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT ... Full text Open Access Link to item Cite

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Conference Blood · November 13, 2019 BackgroundInterferons are recognized as active agents in the treatment of patients with high risk essential thrombocythemia (ET) or polycythemia vera (PV), both in the upfront setting as well as beyond. Several tria ... Full text Cite

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.

Journal Article Blood · October 31, 2019 Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). To further define the role of rIFN-α, we investigated the outcomes of pegylated-rIFN- ... Full text Link to item Cite

Feasibility of myelosuppressive chemotherapy in psychiatric patients on clozapine: A systematic review of the literature.

Journal Article Eur J Haematol · October 2019 OBJECTIVE: Clozapine is the favoured antipsychotic for treatment-refractory schizophrenia, but has a 1%-2% incidence of agranulocytosis. Patients who require chemotherapy therefore pose a unique management dilemma for haematologists, oncologists and psychi ... Full text Link to item Cite

ZCCHC8, the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation.

Journal Article Genes Dev · October 1, 2019 Short telomere syndromes manifest as familial idiopathic pulmonary fibrosis; they are the most common premature aging disorders. We used genome-wide linkage to identify heterozygous loss of function of ZCCHC8, a zinc-knuckle containing protein, as a cause ... Full text Link to item Cite

Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Conference Blood · November 29, 2018 AbstractIntroductionHU is the treatment of choice for patients (pts) with high risk ET/PV, however, PEG has been proposed as an alternative option due to its proposed potenti ... Full text Cite

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

Journal Article J Hematol Oncol · February 22, 2017 BACKGROUND: The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. The primary and planned 3-year analyses of COMFORT-I data demonstra ... Full text Link to item Cite

Diagnosis of Capnocytophaga canimorsus Sepsis by Whole-Genome Next-Generation Sequencing.

Journal Article Open Forum Infect Dis · September 2016 We report the case of a 60-year-old man with septic shock due to Capnocytophaga canimorsus that was diagnosed in 24 hours by a novel whole-genome next-generation sequencing assay. This technology shows great promise in identifying fastidious pathogens, and ... Full text Open Access Link to item Cite

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

Journal Article Biol Blood Marrow Transplant · March 2016 The impact of Janus kinase (JAK) 1/2 inhibitor therapy before allogeneic hematopoietic cell transplantation (HCT) has not been studied in a large cohort in myelofibrosis (MF). In this retrospective multicenter study, we analyzed outcomes of patients who un ... Full text Link to item Cite

The clinical and laboratory evaluation of the patient with erythrocytosis.

Journal Article Eur J Intern Med · June 2015 Erythrocytosis is frequently encountered as an incidental abnormality on laboratory testing that reveals persistent elevation of the hematocrit level (>52% in men and >48% in women). In many cases, erythrocytosis is the manifestation of an underlying cardi ... Full text Link to item Cite

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Journal Article Haematologica · April 2015 In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo in ... Full text Link to item Cite

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Journal Article J Natl Compr Canc Netw · April 2015 The classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), which include essential thrombocythemia, polycythemia vera, and myelofibrosis (MF), are in a new era of molecular diagnosis, ushered in by the identification of the JAK2(V61 ... Full text Link to item Cite

Lung transplantation in telomerase mutation carriers with pulmonary fibrosis.

Journal Article Eur Respir J · July 2014 Lung transplantation is the only intervention that prolongs survival in idiopathic pulmonary fibrosis (IPF). Telomerase mutations are the most common identifiable genetic cause of IPF, and at times, the telomere defect manifests in extrapulmonary disease s ... Full text Link to item Cite

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.

Journal Article Haematologica · February 2014 Prior to Janus kinase inhibitors, available therapies for myelofibrosis were generally supportive and did not improve survival. This analysis compares efficacy outcomes of patients with myelofibrosis in the control arms (placebo [n=154] and best available ... Full text Link to item Cite

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

Journal Article Haematologica · December 2013 COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with intermediate-2 or high-risk myelofibrosis. This analysis of COMFORT-I describes the long-term efficacy and saf ... Full text Link to item Cite

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.

Journal Article Br J Haematol · May 2013 Myelofibrosis (MF) patients can present with a wide spectrum of disease characteristics. We analysed the consistency of ruxolitinib efficacy across patient subgroups in the COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment (COMFORT-I,) a dou ... Full text Link to item Cite

Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.

Journal Article Am J Clin Pathol · December 2012 We describe 41 cases of myeloid neoplasms (MNs) secondary to plasma cell myeloma (PCM). The types of MN included myelodysplastic syndrome (MDS) in 34 (82.9%), acute myeloid leukemia (AML) in 4 (9.8%), and myeloproliferative neoplasm (MPN) or MDS/MPN in 3 ( ... Full text Link to item Cite

Erythropoietin receptor contributes to melanoma cell survival in vivo.

Journal Article Oncogene · March 29, 2012 Erythropoietin (Epo) is widely used clinically to treat anemia associated with various clinical conditions including cancer. Data from several clinical trials suggest significant adverse effect of Epo treatment on cancer patient survival. However, controve ... Full text Link to item Cite

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Journal Article N Engl J Med · March 1, 2012 BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. METHODS: In this double-blind trial, we randomly assigned patients with intermediate-2 or high-risk myelofibrosis to twice-d ... Full text Link to item Cite

Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors.

Journal Article BMC Nephrol · December 12, 2011 BACKGROUND: High-dose erythropoiesis-stimulating agents (ESA) for anemia of chronic kidney disease (CKD) have been associated with adverse clinical outcomes and do not always improve erythropoiesis. We hypothesized that high-dose ESA requirement would be a ... Full text Link to item Cite

Erythropoietin for oncology supportive care.

Journal Article Exp Cell Res · May 15, 2011 Recombinant human erythropoietin (rhEPO), the prototype erythropoiesis-stimulating agent developed in the 1980s, was among the first recombinant human proteins to be marketed for clinical use in the oncology setting. Anemia is a frequent concern in patient ... Full text Link to item Cite

American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.

Journal Article J Clin Oncol · November 20, 2010 PURPOSE: To update American Society of Clinical Oncology/American Society of Hematology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. METHODS: An Update Committee reviewed data published between January 2007 a ... Full text Link to item Cite

American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.

Journal Article Blood · November 18, 2010 PURPOSE: To update American Society of Hematology/American Society of Clinical Oncology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. METHODS: An Update Committee reviewed data published between January 2007 a ... Full text Link to item Cite

Non-erythroid effects of erythropoietin.

Journal Article Haematologica · November 2010 Full text Link to item Cite

Unraveling a sticky paradox.

Journal Article Am J Med · May 2010 Full text Link to item Cite

Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.

Journal Article Exp Hematol · December 2009 OBJECTIVE: Polycythemia vera (PV) is characterized by erythrocytosis associated with the presence of the activating JAK2(V617F) mutation in a variable proportion of hematopoietic cells. JAK2(V617F) is detected in other myeloproliferative neoplasms, does no ... Full text Link to item Cite

Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway.

Journal Article Biochem Biophys Res Commun · February 13, 2009 The role of erythropoietin receptor (EpoR) expression in tumor cells and the potential of EpoR-mediated signaling to contribute to cellular proliferation and invasiveness require further characterization. To determine whether EpoR expression and activation ... Full text Link to item Cite

Failure of terminal erythroid differentiation in EKLF-deficient mice is associated with cell cycle perturbation and reduced expression of E2F2.

Journal Article Mol Cell Biol · December 2008 Erythroid Krüppel-like factor (EKLF) is a Krüppel-like transcription factor identified as a transcriptional activator and chromatin modifier in erythroid cells. EKLF-deficient (Eklf(-/-)) mice die at day 14.5 of gestation from severe anemia. In this study, ... Full text Link to item Cite

Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives.

Journal Article Clin Cancer Res · August 1, 2008 Erythropoiesis-stimulating agents (ESA) used for the treatment of chemotherapy-induced anemia in cancer patients have been associated with adverse outcomes of enhanced tumor progression and impaired survival in a series of recent clinical trials. As clinic ... Full text Link to item Cite

Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation.

Journal Article J Thromb Thrombolysis · August 2008 BACKGROUND AND OBJECTIVE: Internet-based disease management programs have the potential to improve patient care. The objective of this study was to determine whether an interactive, internet-based system enabling supervised, patient self-management of oral ... Full text Link to item Cite

Erythropoiesis-stimulating agents in cancer.

Journal Article J Clin Oncol · June 20, 2008 Full text Link to item Cite

The non-haematopoietic biological effects of erythropoietin.

Journal Article Br J Haematol · April 2008 In the haematopoietic system, the principal function of erythropoietin (Epo) is the regulation of red blood cell production, mediated by its specific cell surface receptor (EpoR). Following the cloning of the Epo gene (EPO) and characterization of the sele ... Full text Link to item Cite

Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression.

Journal Article PLoS One · June 20, 2007 BACKGROUND: The induction of tumor angiogenesis, a pathologic process critical for tumor progression, is mediated by multiple regulatory factors released by tumor and host cells. We investigated the role of the hematopoietic cytokine erythropoietin as an a ... Full text Link to item Cite

Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis.

Journal Article Biochem Biophys Res Commun · March 9, 2007 The cardiotoxic adverse effects of anthracycline antibiotics limit their therapeutic utility as essential components of chemotherapy regimens for hematologic and solid malignancies. Here we show that the hematopoietic cytokine erythropoietin attenuates dox ... Full text Link to item Cite

Deferasirox versus deferoxamine.

Journal Article Blood · July 15, 2006 Full text Link to item Cite

Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity.

Journal Article Mol Cancer Ther · February 2006 Evidence for erythropoietin signaling has been shown in several nonhematopoietic tissues, including many tumor types. Clinically, recombinant erythropoietin treatment of malignancy-related anemia has yet to be definitively associated with any modulation of ... Full text Link to item Cite

Erythropoietin biology in cancer.

Journal Article Clin Cancer Res · January 15, 2006 Erythropoietin (Epo) has long been known to be the principal hematopoietic growth factor that regulates cellular proliferation and differentiation along the erythroid lineage. Recent studies have shown that Epo is a pleiotropic cytokine that is proangiogen ... Full text Link to item Cite

Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling.

Journal Article FASEB J · August 2005 Langendorff-perfused rat hearts treated with EPO exhibited significantly improved postischemic recovery of left ventricular developed pressure (LVDP) and reduced infarct size compared with control hearts. Perfusion with the mitogen/extracellular signal-reg ... Full text Link to item Cite

Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor.

Journal Article Br J Haematol · July 2005 The regeneration of circulating red blood cells in response to anaemia associated with blood loss or haemolysis involves an increased rate of erythropoiesis and expansion of proerythroblasts, the bone marrow precursor cells that terminally differentiate in ... Full text Link to item Cite

Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain.

Journal Article Biochim Biophys Acta · April 15, 2005 Erythropoietin receptor (EPOR) gene mutations leading to truncations of the cytoplasmic, carboxy-terminal region of EPOR have been described in some patients with primary familial and congenital polycythemia (PFCP), a disorder characterized by isolated ery ... Full text Link to item Cite

Cytokine signals through STAT3 promote expression of granulocyte secondary granule proteins in 32D cells.

Journal Article Exp Hematol · March 2005 Featured Publication OBJECTIVE: In a previous study, we showed that activation of a transfected human erythropoietin receptor (EPOR) in the murine myeloid cell line 32D resulted in the development of morphologic features of granulocytic differentiation and expression of the ne ... Full text Link to item Cite

Erythropoietin and erythropoietin receptor expression in human prostate cancer.

Journal Article Mod Pathol · March 2005 Featured Publication Erythropoietin is a hematopoietic cytokine that regulates the production of red blood cells. Erythropoietin is normally produced in the adult kidney in a hypoxia-inducible manner. The recombinant form of human erythropoietin is in clinical use for the prev ... Full text Link to item Cite

Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia.

Journal Article Clin Cancer Res · January 1, 2005 Featured Publication PURPOSE: Erythropoietin, an oxygen-regulated glycoprotein hormone, is a hematopoietic cytokine that stimulates erythropoiesis by binding to its cellular receptor [erythropoietin receptor (EPOR)]. The recombinant form of human erythropoietin is used to prev ... Link to item Cite

Pure red cell aplasia following pegylated interferon alpha treatment.

Journal Article Am J Med · October 15, 2004 Featured Publication Full text Link to item Cite

Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury.

Journal Article FASEB J · June 2004 Featured Publication Erythropoietin (EPO), the principal hematopoietic cytokine that regulates mammalian erythropoiesis, exhibits diverse cellular effects in non-hematopoietic tissues. The physiologic functions of EPO are mediated by its specific cell-surface receptor EPOR. In ... Full text Link to item Cite

A novel role for erythropoietin during fibrin-induced wound-healing response.

Journal Article Am J Pathol · September 2003 Featured Publication In this study, we investigated the role of the hematopoietic cytokine erythropoietin (EPO) during wound healing, the physiological response to tissue injury. We used an in vivo wound-healing assay (fibrin Z-chambers) consisting of fibrin-filled chambers im ... Full text Link to item Cite

Expression of erythropoietin receptor splice variants in human cancer.

Journal Article Biochem Biophys Res Commun · August 8, 2003 Featured Publication Erythropoietin (EPO) regulates mammalian erythropoiesis by binding to its transmembrane receptor EPOR. Recent studies demonstrated functional EPOR expression in human cancer cells. Recombinant human EPO was reported to stimulate the proliferation of monola ... Full text Link to item Cite

Functional significance of erythropoietin receptor expression in breast cancer.

Journal Article Lab Invest · July 2002 Erythropoietin (EPO) is the principal hematopoietic cytokine that regulates mammalian erythropoiesis by binding to its transmembrane receptor EpoR. Recent experimental evidence suggests that the biologic effects of EPO are not limited to the regulation of ... Full text Link to item Cite

Purification and characterization of the yeast-expressed erythropoietin mutant Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis.

Journal Article Blood · June 15, 2002 Featured Publication A drug that specifically inhibits erythropoiesis would be clinically useful. The erythropoietin (Epo) mutant Epo (R103A) could potentially be used for this purpose. Epo (R103A) has a single amino acid substitution of alanine for arginine at position 103. B ... Full text Link to item Cite

A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis.

Journal Article Blood · April 15, 2002 Featured Publication Primary familial erythrocytosis (familial polycythemia) is a rare myeloproliferative disorder with an autosomal dominant mode of inheritance. We studied a new kindred with autosomal dominantly inherited familial erythrocytosis. The molecular basis for the ... Full text Link to item Cite

Functional insufficiency of the system responsible for reactive oxygen species generation by blood neutrophils.

Journal Article Bull Exp Biol Med · August 2001 We studied functional activity of the system responsible for generation of reactive oxygen species by blood neutrophils and involved in pathophysiological mechanisms of bronchopulmonary diseases. Insufficiency of this system can be classified as relative, ... Full text Link to item Cite

Erythropoietin mediates terminal granulocytic differentiation of committed myeloid cells with ectopic erythropoietin receptor expression.

Journal Article Eur J Haematol · August 2001 Featured Publication OBJECTIVES: The precise role of hematopoietic cytokine/cytokine receptor interactions in lineage-restricted hematopoietic differentiation giving rise to mature blood cells of diverse function is incompletely defined. To study lineage-specific effects of cy ... Link to item Cite

Interchangeabelity of cytokine receptor signals during terminal myeloid differentiation: erythropoietin receptor (epor) signals support granulocytic differentiation and induction of myeloid gene expression

Journal Article Blood · December 1, 2000 Hematopoietic cytokines and intracellular signals emanating from their cell surface receptors support the proliferation, viability and differentiation of bone marrow cells. The precise role of cytokine/cytokine receptor interactions in lineage-restricted h ... Cite

Familial polycythemia due to truncations of the erythropoietin receptor.

Journal Article Trans Am Clin Climatol Assoc · 2000 Featured Publication We studied a kindred with dominantly inherited familial erythrocytosis associated with heterozygosity for a deletion of seven nucleotides in exon 8 of the EpoR gene resulting in an EpoR peptide that is truncated by 59 amino acids in its C-terminal intracyt ... Link to item Cite

Molecular diagnosis of hemoglobinopathies and other red blood cell disorders.

Journal Article Semin Hematol · October 1999 Featured Publication This article provides an overview of the techniques currently available for the molecular diagnosis of hemoglobinopathies and other inherited erythrocyte disorders. Advances in both clinical practice and molecular biology have permitted rapid genetic diagn ... Link to item Cite

A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation.

Journal Article Exp Hematol · January 1999 Featured Publication The erythropoietin receptor (EpoR) has been previously shown to contain a cytoplasmic C-terminal negative regulatory domain, experimental deletion or mutation of which leads to increased sensitivity of expressing cells to the effects erythropoietin (Epo). ... Full text Link to item Cite

The distal cytoplasmic domain of the erythropoietin receptor induces granulocytic differentiation in 32D cells.

Journal Article Blood · August 15, 1998 Featured Publication The role of hematopoietic growth factors in lineage commitment and differentiation is unclear. We present evidence that heterologous expression of an erythroid specific receptor allows granulocytic differentiation of a myeloid cell line. We have previously ... Link to item Cite

Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene.

Journal Article Blood · June 15, 1997 Featured Publication Familial erythrocytosis (familial polycythemia) inherited as an autosomal dominant trait has recently been reported to be associated with mutations in the gene encoding the erythropoietin receptor (EpoR) in a small number of families. We studied a new kind ... Link to item Cite

High levels of human gamma-globin gene expression in adult mice carrying a transgene of deletion-type hereditary persistence of fetal hemoglobin.

Journal Article Mol Cell Biol · April 1997 Featured Publication Persistent expression of the gamma-globin genes in adults with deletion types of hereditary persistence of fetal hemoglobin (HPFH) is thought to be mediated by enhancer-like effects of DNA sequences at the 3' breakpoints of the deletions. A transgenic mous ... Full text Link to item Cite

Hematologic disorders and nonimmune hydrops fetalis.

Journal Article Semin Perinatol · December 1995 Featured Publication Hematologic disorders are implicated in approximately 10% to 27% of cases of nonimmune hydrops fetalis. In almost all of these disorders, anemia leading to heart failure, edema, ascites, and anasarca is the final common denominator. The etiology of the ane ... Full text Link to item Cite

Spontaneous delta- to beta-globin switching in K562 human leukemia cells.

Journal Article Blood · February 1, 1992 Featured Publication Previous analysis of the hemoglobin phenotype of the K562 human erythroleukemia cell line showed regulated expression of the epsilon-, zeta-, gamma-, alpha-, and delta-globin genes. Expression of the beta-globin genes has not been previously detected in th ... Link to item Cite

Nocturnal penile tumescence in cigarette smokers with erectile dysfunction.

Journal Article Urology · February 1992 We examined the relationship between cigarette smoking and erectile physiology in 314 men with erectile dysfunction. All of the men studied were currently cigarette smokers. Evaluations included interviews, physical examinations, and polysomnographic asses ... Full text Link to item Cite

Regulated expression of p18, a major phosphoprotein of leukemic cells.

Journal Article J Biol Chem · November 5, 1991 Featured Publication p18 is a phosphoprotein that is present in great abundance in acute leukemia blasts and in less abundance in proliferating lymphocytes. This protein undergoes major changes in its state of phosphorylation upon induction of differentiation of leukemic cells ... Link to item Cite

Prevalence of sleep apnea in men with erectile dysfunction.

Journal Article Urology · September 1990 Sleep studies were performed on 1,025 patients complaining of erectile dysfunction. In addition to standard measures of sleep stage and nocturnal penile tumescence, respiratory activity was evaluated. The number of episodes of sleep apnea per hour (Apnea I ... Full text Link to item Cite